Scandion Oncology

Less than 1K followers

All

Webcasts

Press releases

3rd party

ShowingAll content types

Regulatory press release6/25/2025, 3:00 PM

Delisting of the shares of Scandion Oncology - last day of trading July 11, 2025

Scandion Oncology

Regulatory press release6/25/2025, 12:00 PM

Scandion Oncology has applied for delisting of the company's shares from Nasdaq First North Growth Market

Scandion Oncology

Regulatory press release3/27/2025, 3:00 PM

Scandion Oncology Announces Results of Annual General Meeting

Scandion Oncology

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release3/12/2025, 12:10 PM

Scandion Oncology – Notice convening the Annual General Meeting

Scandion Oncology

Regulatory press release3/12/2025, 12:05 PM

Scandion Oncology - Annual Report 2024

Scandion Oncology

Regulatory press release3/12/2025, 12:00 PM

Scandion Oncology – Q4 & yearend report 2024

Scandion Oncology

Regulatory press release2/26/2025, 5:40 PM

Scandion Oncology CEO Francois Martelet, MD will take over CMO tasks

Scandion Oncology

Regulatory press release2/26/2025, 5:35 PM

Scandion Oncology announces rescheduled publication date for Q4 and Year-end 2024 report

Scandion Oncology

Regulatory press release2/26/2025, 5:30 PM

Scandion Oncology’s Board of Directors emphasize need to find a partner before the Annual General Meeting

Scandion Oncology

Regulatory press release1/13/2025, 6:00 AM

Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer

Scandion Oncology

Regulatory press release11/20/2024, 4:30 PM

Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million

Scandion Oncology

Regulatory press release11/14/2024, 7:30 AM

Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024

Scandion Oncology

Press release11/12/2024, 4:54 PM

Redeye: Scandion Oncology Q3 2024 - Searching for a partner

Scandion Oncology

Scandion Oncology, Audiocast with teleconference, Q3'24

Webcast11/11/2024, 8:00 AM

Scandion Oncology, Audiocast with teleconference, Q3'24

Scandion Oncology

Regulatory press release11/11/2024, 6:00 AM

Scandion Oncology – Interim Report Q3 2024

Scandion Oncology

Press release11/5/2024, 4:00 PM

Invitation to Scandion Oncology webcast and conference call November 11, 2024

Scandion Oncology

Regulatory press release11/4/2024, 7:30 AM

Scandion Oncology announces the start of the exercise period for warrants of series TO 2

Scandion Oncology

Regulatory press release10/31/2024, 7:30 AM

Correction: Scandion Oncology announces exercise price for warrants of series TO 2

Scandion Oncology

Regulatory press release10/30/2024, 4:00 PM

Scandion Oncology announces exercise price for warrants of series TO 2

Scandion Oncology

Press release8/29/2024, 10:26 AM

Redeye: Scandion Oncology Q2 2024 - Partnership represents best hope

Scandion Oncology

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.